In 2022, the minimal residual disease testing market was worth around USD 1,156.8 million, and it is projected to advance at a 15.1% CAGR from 2022 to 2030, hitting USD 3,570.1 million in 2030, according to P&S Intelligence.

1. © P&S Intelligence. All Rights Reserved 1
Minimal Residual Disease
Testing Market Will Reach
USD 3,570.1 Million in
2030

2. © P&S Intelligence. All Rights Reserved 2
In 2022, the minimal residual disease testing market was worth around USD 1,156.8 million, and it is
projected to advance at a 15.1% CAGR from 2022 to 2030, hitting USD 3,570.1 million in 2030, according
to P&S Intelligence.
This development can be ascribed to the increasing occurrence of solid tumors and hematological
malignancies. Furthermore, the rising healthcare spending, also the increasing government and private
expenditure in minimal residual disease studies, are projected to boost the growth of the market in the
future as well.
For minimal residual disease testing, next-generation sequencing and polymerase chain reaction are the
most generally utilized methods, mainly because they offer quick and more-precise outcomes than
others. Furthermore, businesses are concentrating on the growth of innovative and enhanced assays that
will use these methods.

3. © P&S Intelligence. All Rights Reserved 3
North America led the industry, by generating the largest revenue share, of approximately 45% in
2022, mainly due to high R&D and growth expenditure, the existence of key players, increasing
acceptance of technologically enhanced solutions, and the huge number of testing amenities in the
continent.
The increasing occurrence of cancer in the blood-making tissue in the U.S. has surged the probability
of individuals possessing residual malignant cells, which would support the requirement for minimal
residual disease testing. As per the American Cancer Society, in 2022 in the U.S. approximately 34,470
new cases of multiple myeloma and 6,670 new cases of acute lymphocytic leukemia were identified.
Download sample pages of this report: https://www.psmarketresearch.com/market-
analysis/minimal-residual-disease-testing-market/report-sample
In the coming few years, the hospital's category is projected to develop at the highest rate, of more
than 13% CAGR, in the minimal residual disease testing market. This is because of the existence of
cutting-edge diagnostic equipment, coupled with extremely skilled healthcare specialists at such
places.

4. © P&S Intelligence. All Rights Reserved 4
The finding of the remaining cancerous cells plays a vital role in creating up-to-date long-term clinical
decisions after the cancer therapy is finished. Thus, the effectiveness of the analysis is vital for healthcare
insurance businesses to offer financial aid to cancer survivors globally.
The hematological malignancy category is projected to experience a CAGR of over 16% in the coming few
years, mainly because of the increasing occurrence of leukemia throughout the world. In 2022 as per the
data issued by the American Cancer Society, around 8,550 new cases of Hodgkin’s lymphoma were
identified in the U.S., with 3,970 females, and 4,570 males, along with 920 demises. Moreover, survival
rates have significantly amplified in the past, mostly because of the enhancement in the treatment, the
effectiveness of which hinge on the stage of cancer.
Hence, the increasing occurrence of solid tumors and hematological malignancies, and also the rising
healthcare spending, also the increasing government and private expenditure in minimal residual disease
studies, are driving the minimal residual disease testing industry.

5. © P&S Intelligence. All Rights Reserved 5
Disclaimer:
P&S Intelligence always keeps its customers’ interests at the core while carrying out research activities. P&S Intelligence ensures the reliability and accuracy of information and data
provided in its market research publications. However, the information in publications is subject to fluctuations, as it is based on primary interviews of officials from various companies
or organizations. P&S Intelligence is not responsible for any incorrect data provided by the key industry players of the concerned domain. the information or analysis in P&S Intelligence
publications represents opinions based on research and should not be interpreted as statements of fact. Information in this report was believed to be correct at the time of publication,
but cannot be guaranteed. P&S Intelligence does not endorse any product, service, or vendor depicted in its research publications.
All intellectual properties, including trademarks and copyrights, belong to their respective owners and may be protected by copyright. Under no circumstance can these be reproduced
in any form without prior written agreement of their owners.
An order for market research report is intended for internal use of the company only and not for disclosure to third parties or any other publication in general. No service, report, or part
thereof provided by P&S Intelligence can be reproduced, republished, resold, revealed, distributed, circulated, or sublicensed in any medium or form now realized or hereafter become
realized, including but not limited to, all forms of optical-based media, magnetic, electronic, or digital, without a written permission from Prescient & Strategic Intelligence Pvt. Ltd.
psmarketresearch.com
To know more about us, visit our website
For queries related to sales, contact us at:
US/Canada Toll-Free: 1-888-778-7886
International: +1-347-960-6455
India: +91 120 4541 337
enquiry@psmarketresearch.com